RESEARCH TRIANGLE PARK, NC (RTP) – December 11, 2017 – Dignify Therapeutics, LLC, a leading developer of therapies for bladder and bowel dysfunction, announced the appointment of Nadia Rupniak, PhD, as Executive Vice President of Drug Development.
Dr. Rupniak is an internationally recognized neuroscientist and drug developer, with experience in efficacy and safety pharmacology, toxicology, pharmacokinetics and metabolism, regulatory interactions, and the design of clinical studies. Previously, Dr Rupniak was Vice President of Research and Development at CoLucid Pharmaceuticals, where she played a key role in the development of lasmiditan for migraine. Lasmiditan was acquired by Eli Lilly following CoLucid’s successful IPO. Before this, she was a Distinguished Senior Investigator with Merck, where she supported the development of numerous clinical candidates, including Emend ® for emesis and Vioxx ® for pain. Her main interest is in the identification of important therapeutic uses for novel molecules and differentiating their mechanism of action from established therapies.
“We are delighted to have Dr. Rupniak join Dignify as we progress our programs for bladder and bowel voiding disorders towards the clinic,” said Dr. Karl Thor, Chief Scientific Officer of Dignify Therapeutics. “Her experience in bringing specific drug classes through the regulatory approval process is immediately applicable for several of our novel programs designed to allow people to regain control of their bladder and bowel function.”
About Dignify Therapeutics LLC
Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics’ mission is to provide safe, effective, practical and convenient,
pharmaceutical agents to treat bladder and bowel voiding dysfunctions. The Company has been
funded by RA Capital Management, Eshelman Ventures, the North Carolina Biotechnology
Center, NIDDK, NINDS, NICHD, NIA and the One NC Small Business Program. Dignify, a member
of the Blackstone Entrepreneur Network, is located at the First Flight Venture Center in
Research Triangle Park, North Carolina.
PRESS CONTACT
Dignify Therapeutics
Ed Burgard
P.O. Box 13169
2 Davis Drive
Research Triangle Park, NC 27709
Phone: 919-371-8138
Email: eburgard@dignifytherapeutics.com
Website: https://dignifytherapeutics.com
